Long-term safety of biologics in the treatment of psoriasis

Manisha R Panchal,1 Helen Coope,2 D John McKenna,3 Anton B Alexandroff31Department of Dermatology, Sherwood Forest Hospitals, Kingsmill Hospital, Nottinghamshire, 2Novartis Pharmaceuticals UK Ltd, West Sussex, 3Department of Dermatology, University Hospitals of Leicester, Leicester Royal Infirmary,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Panchal MR, Coope H, McKenna DJ, Alexandroff AB
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/915403ad75d74db098f739bee5395718
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:915403ad75d74db098f739bee5395718
record_format	dspace
spelling	oai:doaj.org-article:915403ad75d74db098f739bee53957182021-12-02T01:15:19ZLong-term safety of biologics in the treatment of psoriasis2230-326Xhttps://doaj.org/article/915403ad75d74db098f739bee53957182013-12-01T00:00:00Zhttp://www.dovepress.com/long-term-safety-of-biologics-in-the-treatment-of-psoriasis-a15269https://doaj.org/toc/2230-326X Manisha R Panchal,1 Helen Coope,2 D John McKenna,3 Anton B Alexandroff31Department of Dermatology, Sherwood Forest Hospitals, Kingsmill Hospital, Nottinghamshire, 2Novartis Pharmaceuticals UK Ltd, West Sussex, 3Department of Dermatology, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester, UKAbstract: Biologics are novel and important agents in the treatment of severe psoriasis. These agents block specific molecular steps in the inflammatory cascade, thereby reducing activation and proliferation of keratinocytes. Prescreening for biologic agents and careful monitoring of patients is important. There are four biologics currently licensed and used in the treatment of psoriasis in the European Union. This is an evidence-based review examining clinical trials and focusing on the long-term safety data for four biologic agents. Current British Association of Dermatology guidance for the use of biologics in psoriasis and guidelines on the management of psoriasis from the National Institute for Health and Clinical Excellence have been used. Advances on safety information since 2009 in clinical trials are reviewed. The results show that overall there is no statistical significance in the incidence of adverse effects of biologics versus placebo. However, there are serious adverse effects that are reported for biologics that need to be assessed for and addressed promptly. Results of studies discussing major adverse cardiovascular events are also reviewed.Keywords: psoriasis, biologic agents, safety profile, major cardiovascular eventsPanchal MRCoope HMcKenna DJAlexandroff ABDove Medical PressarticleDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol 2014, Iss default, Pp 1-9 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Dermatology RL1-803
spellingShingle	Dermatology RL1-803 Panchal MR Coope H McKenna DJ Alexandroff AB Long-term safety of biologics in the treatment of psoriasis
description	Manisha R Panchal,1 Helen Coope,2 D John McKenna,3 Anton B Alexandroff31Department of Dermatology, Sherwood Forest Hospitals, Kingsmill Hospital, Nottinghamshire, 2Novartis Pharmaceuticals UK Ltd, West Sussex, 3Department of Dermatology, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester, UKAbstract: Biologics are novel and important agents in the treatment of severe psoriasis. These agents block specific molecular steps in the inflammatory cascade, thereby reducing activation and proliferation of keratinocytes. Prescreening for biologic agents and careful monitoring of patients is important. There are four biologics currently licensed and used in the treatment of psoriasis in the European Union. This is an evidence-based review examining clinical trials and focusing on the long-term safety data for four biologic agents. Current British Association of Dermatology guidance for the use of biologics in psoriasis and guidelines on the management of psoriasis from the National Institute for Health and Clinical Excellence have been used. Advances on safety information since 2009 in clinical trials are reviewed. The results show that overall there is no statistical significance in the incidence of adverse effects of biologics versus placebo. However, there are serious adverse effects that are reported for biologics that need to be assessed for and addressed promptly. Results of studies discussing major adverse cardiovascular events are also reviewed.Keywords: psoriasis, biologic agents, safety profile, major cardiovascular events
format	article
author	Panchal MR Coope H McKenna DJ Alexandroff AB
author_facet	Panchal MR Coope H McKenna DJ Alexandroff AB
author_sort	Panchal MR
title	Long-term safety of biologics in the treatment of psoriasis
title_short	Long-term safety of biologics in the treatment of psoriasis
title_full	Long-term safety of biologics in the treatment of psoriasis
title_fullStr	Long-term safety of biologics in the treatment of psoriasis
title_full_unstemmed	Long-term safety of biologics in the treatment of psoriasis
title_sort	long-term safety of biologics in the treatment of psoriasis
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/915403ad75d74db098f739bee5395718
work_keys_str_mv	AT panchalmr longtermsafetyofbiologicsinthetreatmentofpsoriasis AT coopeh longtermsafetyofbiologicsinthetreatmentofpsoriasis AT mckennadj longtermsafetyofbiologicsinthetreatmentofpsoriasis AT alexandroffab longtermsafetyofbiologicsinthetreatmentofpsoriasis
_version_	1718403213406765056

Long-term safety of biologics in the treatment of psoriasis

Ejemplares similares